Literature DB >> 12770508

Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis.

A Ferrari1, E Sternieri, E Ferraris, A Bertolini.   

Abstract

Patients suffering from migraine take drugs for many years in order either to relieve or to prevent recurrent migraine attacks. When two or more drugs are co-administered, there is always the possibility of drug-drug interaction. Interactions can be either kinetic or dynamic. The former are the most frequent ones. Mechanisms of kinetic interaction can be different, but the most common are represented by the induction or inhibition of enzymes of the cytochromes p450 (CYP) system. This system plays an important role in the disposition of a large number of drugs, including those used for migraine. This review examines the interactions between triptans-the most effective drugs for the therapy of migraine attacks-and drugs for migraine prophylactic treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12770508

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

1.  The pharmacological management of migraine, part 2: preventative therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-08

2.  Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.

Authors:  Giovanna Gentile; Serena Missori; Marina Borro; Alisa Sebastianelli; Maurizio Simmaco; Paolo Martelletti
Journal:  J Headache Pain       Date:  2010-03-06       Impact factor: 7.277

3.  Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.

Authors:  Yusuke Masuo; Shushi Nagamori; Aoi Hasegawa; Kazuki Hayashi; Noriyoshi Isozumi; Noritaka Nakamichi; Yoshikatsu Kanai; Yukio Kato
Journal:  Pharm Res       Date:  2017-03-30       Impact factor: 4.200

Review 4.  [A clinical challenge. Pragmatic treatment of migraine and concomitant depression].

Authors:  T P Jürgens; E Leinisch; H J Koch
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

5.  Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.

Authors:  Anna Ferrari; Diego Pinetti; Alfio Bertolini; Ciro Coccia; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2008-01-08       Impact factor: 2.953

Review 6.  Antidepressants in long-term migraine prevention.

Authors:  Horst J Koch; Tim P Jürgens
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.

Authors:  Shivang Joshi; Stewart J Tepper; Sylvia Lucas; Soeren Rasmussen; Rob Nelson
Journal:  Headache       Date:  2021-06       Impact factor: 5.887

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.